AbbVie, Gilgamesh partner on psychiatric therapies
引进/卖出并购临床2期
AbbVie and Gilgamesh Pharmaceuticals have entered a collaboration and option-to-license agreement to develop next-generation therapies for psychiatric disorders.
Under the terms of the agreement, AbbVie will make an initial payment of $65 million to Gilgamesh, with potential for up to $1.95 billion in option fees and milestone payments. Additionally, Gilgamesh is eligible to receive tiered royalties on net sales, contingent upon the successful development and commercialization of the therapies.
This partnership will leverage AbbVie's expertise in psychiatry and Gilgamesh's innovative research platform to create novel neuroplastogens designed to treat conditions such as mood and anxiety disorders. Neuroplastogens aim to offer the clinical benefits of classic psychedelic compounds without their significant psychoactive effects.
New York-based Gilgamesh was founded in 2019, with a focus on treating mental health conditions with novel compounds that capture the therapeutic benefits of psychedelics.
For AbbVie, the collab comes amid a push to bolster its presence in the neuroscience sector, with the drugmaker spending $8.7 billion to acquire Cerevel Therapeutics back in December. The move gave AbbVie access to Cerevel's pipeline targeting psychiatric and neurological disorders, including emraclidine, a positive allosteric modulator undergoing phase 2 trials for schizophrenia.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。